Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 75, Issue 4, Pages 422-434Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.11.031
Keywords
diabetes; heart failure; renal function; SGLT2 inhibitor
Categories
Funding
- German Research Foundation (Deutsche Forschungsgemeinschaft) [ZE 1109/1-1]
- AstraZeneca
- Daiichi-Sankyo
- GlaxoSmithKline
- Merck
- Novartis
Ask authors/readers for more resources
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class. This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i. (C) 2020 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available